MedTrace Logo

A Study of KY1005 in Patients With Moderate to Severe Atopic Dermatitis

NCT03754309 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 89

Last updated 2023-01-27

No results posted yet for this study

Summary

The purpose of this research study is to investigate if KY1005 results in improvement of eczema when given to participants with moderate to severe disease. Side effects of KY1005 will also be explored.

Conditions

  • Dermatitis, Atopic

Interventions

DRUG

KY1005

A human anti-OX40 ligand monoclonal antibody

DRUG

Placebo

Matched placebo

Sponsors & Collaborators

  • Kymab Limited

    lead INDUSTRY

Principal Investigators

  • Stephan Weidinger, MaHM · University Hospital Schleswig-Holstein, 24105 Kiel, Germany

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-13
Primary Completion
2020-05-12
Completion
2020-10-08

Countries

  • Germany
  • Poland
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03754309 on ClinicalTrials.gov